Sep. 20, 2025 at 12:52 PM ET6 min read

Oppenheimer Raises AQST Target Price, Shares Surge

Tim BohenAvatar
Written by Tim Bohen Reviewed by Ben Sturgill Fact-checked by Ellis Hobbs

Aquestive Therapeutics Inc.’s stocks have been trading up by 15.34 percent, reflecting investor optimism driven by positive sentiment.

Key Highlights

  • The FDA has informed Aquestive Therapeutics that an advisory committee meeting is not necessary for Anaphylm Sublingual Film’s approval. The decision has strengthened investor confidence, explaining the recent uptick in share prices.
  • LifeSci Capital recently initiated coverage of the company with an Outperform rating and set a bullish $10 price target. This move underscores a positive long-term outlook for AQST’s innovative treatments.
  • Oppenheimer raised the company’s price target to $8 from $7 following promising news about Anaphylm. The updated target reflects investor optimism and has sent shares soaring by nearly 44%.

Healthcare industry expert:

Analyst sentiment – positive

Aquestive Therapeutics (AQST) currently faces significant financial challenges, as evidenced by its Gross Margin of 61.1% juxtaposed with substantial negative profitability metrics, such as an EBIT margin of -134.2% and a Total Profit Margin of -147.38%. The company’s revenue trajectory has been declining over the past 3 to 5 years, contributing to a depressed financial condition. With a Price-to-Sales ratio of 11.16 and no positive PE ratio, AQST’s valuation is strained. Operating cash flow remains in the red at -$7.914 million, indicating persistent financial instability despite a relatively healthy Current Ratio of 3.5. The main financial insights point to heavy losses, high leverage, and an urgent need for operational turnaround.

On the technical front, AQST’s weekly price patterns exhibit volatility, with key resistance at $5.31 as seen on September 18th, and strong support established in the $4.80 to $4.87 range earlier in the month. The recent channel of $4.86 to $5.69 highlights a generally upward trend, especially given the significant upward movement past $5.18 on September 18th and further to $5.69 by September 19th. The 5-minute candle data further solidifies this uptrend, suggesting room for continuation if volumes sustain above average. A trading strategy would target accumulations near support at $5.18, with an exit point poised at $5.72, given heightened recent volume near these levels, confirming a break is eminent past this threshold.

Recent news provides positive catalysts for AQST, with the FDA’s decision not to require an Advisory Committee Meeting for Anaphylm being a game changer, as evidenced by rising share prices and adjusted analyst price targets between $8 and $10. The news spurred a swift market reaction, elevating shares by over 43%, indicative of improved investor confidence. With upcoming significant milestones such as the PDUFA target action date set for January 31, 2026, AQST aligns positively against its sector benchmarks. Consequently, Anaphylm’s forthcoming FDA decision and minimal resistance up to $8 strengthen the growth outlook. Given these dynamics, AQST’s prospects are reasonably optimistic with tentative resistance near $8.78 and support maintained above $5.50.

Candlestick Chart

More Breaking News

Weekly Update Sep 15 – Sep 19, 2025: On Saturday, September 20, 2025 Aquestive Therapeutics Inc. stock [NASDAQ: AQST] is trending up by 15.34%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

AQST’s recent stock movements reflect notable momentum driven by positive regulatory news. Over recent trading days, AQST’s shares have shown a pattern of growth. Starting from $5.14, with a dip on September 16, but bouncing back, reaching a high close of $5.6978 following bullish announcements. The intraday sessions have seen volatile yet upward trends, peaking to $5.67 after a rally.

Financially, the company navigates through profitability challenges with apparent losses reflected in several key ratios like a negative EBIT margin of -134.2%. Despite these profitability hurdles, AQST exhibits a robust current ratio of 3.5, indicative of strong liquidity to cover short-term obligations. With strategic innovations like Anaphylm awaiting key regulatory milestones, these developments could be pivotal for AQST’s future trajectory and financial health.

Overall, the existing financial environment, intertwined with recent optimistic market reception to its therapeutic underpinnings, builds a complex but exciting narrative for analysts and investors considering short-term trading over long-term investments.

Conclusion

The convergence of FDA’s regulatory leniencies, coupled with strategic analyst endorsements, has set a buoyant tone for AQST in the near-term market landscape. Although current financials project liquidity, earnings remain under pressure required to buffer continuous R&D investments and operational expenditures. As Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.” This philosophy underscores the importance of strategy in trading activities, particularly with AQST’s current position. The focal point now rests heavily on effective execution of financial and market strategies tied to Anaphylm’s rollout, amid unpredictable market volatility. Traders, particularly within the penny stock arena, might find AQST’s unfolding narrative heavily resourceful, balancing innovation-driven catalysts with disciplined financial oversight in quest for market outperformance.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.